Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer-related mortality worldwide.1 Despite therapeutic ...
IL-2 is clinically validated as an immunotherapeutic, but its use is limited by toxicity issues. AZD-6750 is an approach from ...
In a recent study published in Nature Methods, researchers developed "scAtlasVAE," a deep-learning model to integrate large-scale single-cell ribonucleic acid (RNA) sequencing (scRNA-seq) data, ...
Background Chronic hepatitis B virus (HBV) infection disproportionately affects people living with HIV, who are often excluded from functional cure studies. Objective This study investigates CD8+ T ...
Two studies suggest that T cells with stem-cell-like properties could work with antibody therapies to control HIV after a ...
Immorta Bio today announced the publication of a landmark preclinical study in the Journal of Translational Medicine demonstrating that its novel immunotherapy, SenoVax(TM), dramatically reduces ...
News-Medical.Net on MSN
Killer T cell traits explain why some people achieve long-term HIV remission after treatment
Researchers led by a team from Mass General Brigham and the Ragon Institute have discovered why some people living with HIV who are given a treatment called broadly neutralizing anti-HIV antibodies ...
The Phase 1 ragistomig study achieved its objective, as the new Q6W extended dosing interval produced strong anti-tumor efficacy in PD-L1-non-responders, with an improved safety profile The interim ...
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...
Immorta Bio today announced the publication of a landmark preclinical study in the Journal of Translational Medicine demonstrating that its novel immunotherapy, SenoVax™, dramatically reduces multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback